In postmenopausal women with osteoporosis, romosozumab followed by alendronate reduced fractures vs alendronate alone

ACP Journal Club16 January 2018In postmenopausal women with osteoporosis, romosozumab followed by alendronate reduced fractures vs alendronate aloneCalvin Hirsch, MDCalvin Hirsch, MDUC Davis Medical Center, Sacramento, California, USA (C.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2018-168-2-003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationSaag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417-27. https://pubmed.ncbi.nlm.nih.gov/28892457Clinical Impact RatingsGIM/FP/GP: Endocrinology: Geriatrics: Rheumatology: References1 Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585-94. [PMID: 28755782] Google Scholar2 Anagnostis P, Paschou SA, Mintziori G, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23-30. [PMID: 28539165] Google Scholar3 He XW, Wang E, Bao YY, et al. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke. Atherosclerosis. 2016;253:22-8. [PMID: 27573735] Google Scholar4 Matthijs Blankesteijn W, Hermans KC. Wnt signaling in atherosclerosis. Eur J Pharmacol. 2015;763:122-30. [PMID: 25987418] Google Scholar Author, Article, and Disclosure InformationAffiliations: UC Davis Medical Center, Sacramento, California, USA (C.H.)This article was published at Annals.org on 2 January 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMiR-27a-3p promotes the osteogenic differentiation by activating CRY2/ERK1/2 axisShikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways 16 January 2018Volume 168, Issue 2Page: JC3KeywordsBone mineral densityHip fracturesOsteoporosisPopulation statisticsProteinsRheumatologyRisk ratioSerious adverse eventsStrokeSubcutaneous injections ePublished: 16 January 2018 Issue Published: 16 January 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...